{"id":"butedronic-acid","rwe":[],"tags":[{"label":"butedronic acid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Osteoporosis","category":"indication"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["butedronic acid"],"offLabel":[],"synonyms":["butedronic acid"],"timeline":[],"ecosystem":[{"indication":"Osteoporosis","otherDrugs":[{"name":"abaloparatide","slug":"abaloparatide","company":"Radius Health Inc"},{"name":"calcium citrate","slug":"calcium-citrate","company":""},{"name":"calcium gluconate","slug":"calcium-gluconate","company":""},{"name":"calcium phosphate","slug":"calcium-phosphate","company":""}],"globalPrevalence":200000000}],"mechanism":{"modality":"Small Molecule","drugClass":"butedronic acid","explanation":"Think of osteoclasts like demolition crews that break down old buildings. Butedronic acid is like a construction worker that stops the demolition crew from doing their job, allowing the bone to stay stronger. This helps to slow down bone loss and reduce the risk of fractures.","oneSentence":"Butedronic acid works by inhibiting osteoclast activity, which are cells responsible for breaking down bone tissue.","technicalDetail":"Butedronic acid acts as a bisphosphonate, a class of drugs that bind to hydroxyapatite in bone tissue and inhibit osteoclast-mediated bone resorption through a mechanism involving the inhibition of farnesyl pyrophosphate synthase and subsequent disruption of the mevalonate pathway."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3052","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BUTEDRONIC ACID","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:09:25.098330","biosimilars":[],"competitors":[],"genericName":"butedronic acid","indications":{"approved":[{"name":"Osteoporosis","source":"DrugCentral","snomedId":64859006,"regulator":"FDA","usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"26PB1U68YF","INN_ID":"6239","UMLSCUI":"C2347239","ChEMBL_ID":"CHEMBL2106599","DRUGBANK_ID":"DB16004","PUBCHEM_CID":"189891"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":2108112,"therapeuticAreas":["Bone"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"BUTEDRONIC ACID","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Butedronic acid is a small molecule drug in the butedronic acid class, originally developed by an unknown entity and currently owned by an unknown entity. It is used to treat osteoporosis, a condition characterized by weakened bones. The exact mechanism of action is not specified, but it is believed to work by inhibiting bone resorption. The commercial status of butedronic acid is unclear, and it may be patented or available as a generic medication. Key safety considerations include unknown side effects and interactions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}